In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
Open Access
- 30 May 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 43
Abstract
Background Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on immunotherapy have limited additional standard options. Given evidence of synergism between radiation therapy (RT) and immunotherapy, two patients progressing on PD-1 inhibition were referred for short-course RT. Case presentation Two patients were found to have progressive mMCC on PD-1 inhibitor therapy and were treated with single-fraction palliative RT. Both patients were observed to have local control at irradiated regions, as well as durable abscopal response at unirradiated, out-of-field, sites of metastatic disease. Conclusions Short-course RT is a compelling strategy that could be a means to augment response in patients with mMCC who show progression on immune checkpoint blockade. Ongoing clinical trials are investigating the relationship between RT and immunotherapy in mMCC.Keywords
This publication has 21 references indexed in Scilit:
- Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma ManagementSurgical Oncology Clinics of North America, 2017
- Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinomaFuture Oncology, 2017
- A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic MelanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune TherapyJournal of Oncology Practice, 2016
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaNew England Journal of Medicine, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Single‐fraction radiation therapy in patients with metastatic Merkel cell carcinomaCancer Medicine, 2015
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapyOncoImmunology, 2014
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006